Mogrify, a UK company which aims to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards 2020.
The awards acknowledge the potential of Mogrify’s proprietary suite of platform technologies that utilise a systematic big-data approach to direct cellular conversion and the maintenance of cell identity, to accelerate the development of regenerative cell and in vivo reprogramming therapies.
The company’s technologies, MOGRIFY and EpiMOGRIFY, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.
Mogrify will use these platforms to engineer therapeutic cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies, and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.
Pierre-Louis Joffrin, CDO, Mogrify, said: “We are honoured to have been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards. We have an outstanding team of cellular reprogramming experts at Mogrify and this award is testament to their delivery of scientific, commercial and operational excellence.”